Literature DB >> 22653683

Antibodies and carbohydrate ligands binding to DC-SIGN differentially modulate receptor trafficking.

Paul J Tacken1, Menno Ter Huurne, Ruurd Torensma, Carl G Figdor.   

Abstract

DCs are regarded as key APCs that initiate humoral and cellular immune responses. Consequently, targeted delivery of Ag toward DC-specific receptors enhances vaccine efficacy. DC-SIGN is a C-type lectin receptor that facilitates DC-specific delivery of Ag. This is accomplished by conjugating Ag to receptor-specific Ab or carbohydrate ligands that bind to its carbohydrate recognition domain. Here, we investigated the fate of DC-SIGN following receptor triggering with Ab. Both whole and single-chain Ab induced rapid internalization of about half of the surface receptor molecules. Biochemical studies showed that about half of the receptor molecules were still intracellular after 3 h, while minimal or no resurfacing of internalized or newly synthesized unbound DC-SIGN molecules was observed. Prolonged exposure of DCs to DC-SIGN Ab, but not carbohydrate ligands, resulted in reduced receptor expression levels, which lasted up to 2 days following removal of the Ab. In addition, exposure to DC-SIGN Ab reduced the ability of the receptor to internalize. Consequently, DC-SIGN showed a poor ability to accumulate targeting Abs within DCs. Vaccine efficacy may therefore be enhanced by strategies increasing the amount of Ag entering via a single receptor molecule, such as the use of targeting moieties allowing DC-SIGN recycling or Ab-coated vaccine carriers.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22653683     DOI: 10.1002/eji.201142258

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  11 in total

Review 1.  Trial watch: dendritic cell vaccination for cancer immunotherapy.

Authors:  Jenny Sprooten; Jolien Ceusters; An Coosemans; Patrizia Agostinis; Steven De Vleeschouwer; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi; Abhishek D Garg
Journal:  Oncoimmunology       Date:  2019-07-18       Impact factor: 8.110

Review 2.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

Review 3.  Trial watch: Dendritic cell-based anticancer immunotherapy.

Authors:  Abhishek D Garg; Monica Vara Perez; Marco Schaaf; Patrizia Agostinis; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-05-12       Impact factor: 8.110

4.  Antigen structure affects cellular routing through DC-SIGN.

Authors:  Cassie M Jarvis; Daniel B Zwick; Joseph C Grim; Mohammad Murshid Alam; Lynne R Prost; Jaye C Gardiner; Soyeong Park; Laraine L Zimdars; Nathan M Sherer; Laura L Kiessling
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-03       Impact factor: 11.205

Review 5.  Targeting the C-type lectins-mediated host-pathogen interactions with dextran.

Authors:  Sergey Pustylnikov; Divya Sagar; Pooja Jain; Zafar K Khan
Journal:  J Pharm Pharm Sci       Date:  2014       Impact factor: 2.327

6.  The Consequences of Multiple Simultaneous C-Type Lectin-Ligand Interactions: DCIR Alters the Endo-Lysosomal Routing of DC-SIGN.

Authors:  Juan J García-Vallejo; Karien Bloem; Léon M J Knippels; Johan Garssen; Sandra J van Vliet; Yvette van Kooyk
Journal:  Front Immunol       Date:  2015-03-10       Impact factor: 7.561

7.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Lorenzo Galluzzi; Laura Senovilla; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-10-01       Impact factor: 8.110

Review 8.  Trial watch: Dendritic cell-based interventions for cancer therapy.

Authors:  Erika Vacchelli; Ilio Vitale; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fučíková; Isabelle Cremer; Jérôme Galon; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2013-07-29       Impact factor: 8.110

Review 9.  Dendritic cell-targeted vaccines.

Authors:  Lillian Cohn; Lélia Delamarre
Journal:  Front Immunol       Date:  2014-05-30       Impact factor: 7.561

10.  Mouse DC-SIGN/CD209a as Target for Antigen Delivery and Adaptive Immunity.

Authors:  Sjoerd T T Schetters; Laura J W Kruijssen; Matheus H W Crommentuijn; Hakan Kalay; Jordi Ochando; Joke M M den Haan; Juan J Garcia-Vallejo; Yvette van Kooyk
Journal:  Front Immunol       Date:  2018-05-07       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.